News May 31, 2022 RetinAI enters a multi-year software license agreement with Novartis Building on their existing relationship, Bern-based RetinAI and pharma giant Novartis have entered a long-term collaboration with a multi-year so...
News May 19, 2022 Kodiak Sciences inaugurates its purpose-built bioconjugation facility in Visp To support potential commercial manufacture of its KSI-301 candidate, Kodiak Sciences has launched a purpose-built bioconjugation facility in Lon...
News May 18, 2022 Cell and gene therapy specialist Cytiva opens new facility in Grens Global life sciences leader Cytiva is opening a new manufacturing in Grens, which will also house the company’s Center of Excellence for cell and...
News May 11, 2022 Eurostars grants CEIDOS and Limula EUR 1.14 million for an innovative device In collaboration with Limula, Valais-based CEIDOS has received a grant of EUR 1.14 million from Eurostars to develop a platform dedicated to the ...
News May 10, 2022 Michael J. Fox Foundation awards Asceneuron a grant to treat Parkinson’s disease Committed to accelerating research into novel Parkinson’s Disease therapies, The Michael J. Fox Foundation for Parkinson’s Research is again awar...
News Apr 28, 2022 Resistell seeking to further develop test to combat antibiotic resistance The start-up Resistell has launched a study looking into the applicability of a test against antibiotic resistances that is being funded by an in...
News Apr 26, 2022 Vaud-based cell imaging specialist Nanolive raises USD 20 million A leader in the field of live cell imaging and analysis, Nanolive has successfully completed its first financing round in the amount of USD 20 mi...
News Apr 25, 2022 New Metrohm analysis method to assess the quality of food Metrohm has successfully further developed the Rancimat method. This is used to determine the rancidity of edible oils and fats in foodstuffs wit...
News Apr 19, 2022 Basler startup receives 46 million Swiss francs for cell therapy Cimeio Therapeutics has received initial financing amounting to 46 million Swiss francs from Versant Ventures. The startup established by the Uni...
News Mar 15, 2022 Leman Biotech raises USD 11 million for its immunotherapy boosting protein EPFL spin-off Leman Biotech has raised USD 11 million for its protein that can improve the effectiveness of immunotherapy drugs used to treat som...
News Mar 08, 2022 BioArk Monthey’s technology site expands Following a first expansion in 2015, the technology site specialized in life sciences, BioArk Monthey, grows once more with the addition of a thi...
News Mar 02, 2022 Vaccines unique to each patient and cancer are being tested at the CHUV Two clinical trials on anti-cancer vaccines have just started at the Lausanne University Hospital (CHUV). Their groundbreaking nature could revol...
News Feb 23, 2022 ACROBiosystems establishes presence in the Basel Area ACROBiosystems ,which is headquartered in Beijing, has selected the Basel Area as the location for its first European site. From here, the biopha...
News Feb 16, 2022 Global recognition for Ticino oncology The lymphoma group of the Institute of Oncological Research and the Oncological Institute of Southern Switzerland has published a guide to detect...
News Feb 14, 2022 Biopôle start-up Adaptyv Biosystems to build the most powerful protein engineering platform Having raised CHF 2.5 million in a pre-seed funding round led by Wingman Ventures, start-up Adaptyv Biosystems is set to create the world’s large...
News Feb 08, 2022 AMR Action Fund opens European office in Basel The AMR Action Fund has moved into its new European office in Basel. The venture fund is the largest public-private partnership for the developme...
News Feb 04, 2022 Test can recognize nine most common types of cancer Researchers at System Biologie AG from the Greater Zurich Area and HealthBiocare GmbH based in Vienna have discovered a new concept for the early...
News Feb 01, 2022 Merck acquires Geneva-based biopharmaceutical company Chord Therapeutics Chord Therapeutics, a clinical stage biopharmaceutical company developing drugs for rare neuroinflammatory diseases, is being acquired by Merck.